AAAAAA
Results:
1-10
|
Results: 10
Authors:
Pierga, JY
Robain, M
Jouve, M
Asselain, B
Dieras, V
Beuzeboc, P
Palangie, T
Dorval, T
Extra, JM
Scholl, S
Pouillart, P
Citation: Jy. Pierga et al., Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, ANN ONCOL, 12(2), 2001, pp. 231-237
Authors:
Pierga, JY
Asselain, B
Jouve, M
Dieras, V
Carton, M
Laurence, V
Girre, V
Beuzeboc, P
Palangie, T
Dorval, T
Pouillart, P
Citation: Jy. Pierga et al., Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy, CANCER, 91(6), 2001, pp. 1079-1089
Authors:
Vincent-Salomon, A
Carton, M
Freneaux, P
Palangie, T
Beuzeboc, P
Mouret, E
de Cremoux, P
Coue, O
Zafrani, B
Nicolas, A
Clough, K
Fourquet, A
Pouillart, P
Sastre-Garau, X
Citation: A. Vincent-salomon et al., ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy, EUR J CANC, 36(5), 2000, pp. 586-591
Authors:
Robain, M
Pierga, JY
Jouve, M
Asselain, B
Dieras, V
Beuzeboc, P
Palangie, T
Dorval, T
Extra, JM
Scholl, S
Pouillart, P
Citation: M. Robain et al., Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer, EUR J CANC, 36(18), 2000, pp. 2301-2312
Authors:
Macquart-Moulin, G
Viens, P
Palangie, T
Bouscary, ML
Delozier, T
Roche, H
Janvier, M
Fabbro, M
Moatti, JP
Citation: G. Macquart-moulin et al., High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: Does impact on quality of life jeopardize feasibility and acceptability of treatment?, J CL ONCOL, 18(4), 2000, pp. 754-764
Authors:
Pierga, JY
Mouret, E
Dieras, V
Laurence, V
Beuzeboc, P
Dorval, T
Palangie, T
Jouve, M
Vincent-Salomon, A
Scholl, S
Extra, JM
Asselain, B
Pouillart, P
Citation: Jy. Pierga et al., Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer, BR J CANC, 83(11), 2000, pp. 1480-1487
Authors:
Braud, AC
Asselain, B
Scholl, S
De la Rochefordiere, A
Palangie, T
Dieras, V
Pierga, JY
Dorval, T
Jouve, M
Beuzeboc, P
Pouillart, P
Citation: Ac. Braud et al., Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?, EUR J CANC, 35(3), 1999, pp. 392-397
Authors:
Palangie, T
Pierga, JY
Pouillart, P
Citation: T. Palangie et al., Dose-intense salvage therapy after neoadjuvant chemotherapy: feasibility and preliminary results, CANC CHEMOT, 44, 1999, pp. S24-S25
Authors:
Beuzeboc, P
Scholl, S
Garau, XS
Vincent-Salomon, A
de Cremoux, P
Couturier, J
Palangie, T
Pouillard, P
Citation: P. Beuzeboc et al., Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene, B CANCER, 86(6), 1999, pp. 544-548
Authors:
Viens, P
Palangie, T
Janvier, M
Fabbro, M
Roche, H
Delozier, T
Labat, JP
Linassier, C
Audhuy, B
Feuilhade, F
Costa, B
Delva, R
Cure, H
Rousseau, F
Guillot, A
Mousseau, M
Ferrero, JM
Bardou, VJ
Jacquemier, J
Pouillart, P
Citation: P. Viens et al., First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), BR J CANC, 81(3), 1999, pp. 449-456
Risultati:
1-10
|